Microbiological Characteristics of Acute Prostatitis After Transrectal Prostate Biopsy
Authors:
Open Access
- 1 January 2013
- journal article
- Published by The Korean Urological Association in Korean Journal of Urology
- Vol. 54 (2) , 117-22
Abstract
We aimed to identify microbiological characteristics in patients with acute prostatitis after transrectal prostate biopsy to provide guidance in the review of prevention and treatment protocols. A retrospective analysis of medical records was performed in 1,814 cases who underwent prostate biopsy at Seoul St. Mary's Hospital and St. Vincent's Hospital over a 5 year period from 2006 to 2011. Cases in which acute prostatitis occurred within 7 days after the biopsy were investigated. Before starting treatment with antibiotics, sample collections were done for culture of urine and blood. Culture and drug susceptibility was identified by use of a method established by the Clinical and Laboratory Standards Institute. A total of 1,814 biopsy procedures were performed in 1,541 patients. For 1,246 patients, the procedure was the first biopsy, whereas for 295 patients it was a repeat biopsy. Twenty-one patients (1.36%) were identified as having acute bacterial prostatitis after the biopsy. Fifteen patients (1.2%) had acute prostatitis after the first biopsy, and 6 patients (2.03%) experienced acute prostatitis after a repeat biopsy. Even though the incidence of acute bacterial prostatitis was higher after repeat biopsy than that after the first biopsy, there was no statistically significant intergroup difference in terms of incidence (χ(2)=1.223, p=0.269). When the collected urine and blood samples were cultured, Escherichia coli was found in samples from 15 patients (71.4%), Klebsiella pneumoniae in 3 patients (14.3%), Enterobacter intermedius in 1 patient (4.8%), E. aerogenes in 1 patient (4.8%), and Pseudomonas aeruginosa in 1 patient (4.8%). A fluoroquinolone-resistant strain was confirmed in 5 cases (23.8%) in total. Three cases of E. coli and 1 case of Klebsiella had extended-spectrum β-lactamase activity. Empirical treatment of acute prostatitis should be done with consideration of geographical prevalence and drug resistance. This study will provide meaningful information for the management of acute prostatitis after transrectal prostate biopsy.Keywords
This publication has 33 references indexed in Scilit:
- A Comparative Study of Clinical Symptoms and Treatment Outcomes of Acute Bacterial Prostatitis According to Urine CultureKorean Journal of Urology, 2011
- Risk Factors for Acute Prostatitis after Transrectal Biopsy of the ProstateKorean Journal of Urology, 2010
- Prospective assessment of the efficacy of single dose versus traditional 3‐day antimicrobial prophylaxis in 12‐core transrectal prostate biopsyInternational Journal of Urology, 2008
- Acute bacterial prostatitis in Korea: clinical outcome, including symptoms, management, microbiology and course of diseaseInternational Journal of Antimicrobial Agents, 2008
- Estudio comparativo entre tobramicina y tobramicina más ciprofloxacino como profilaxis para la biopsia transrectal de próstataActas Urológicas Españolas, 2006
- Epidemiology and risk factors for extended-spectrum β-lactamase-producing organisms: A case control study at a tertiary care center in LebanonAmerican Journal of Infection Control, 2005
- Incidence of Urinary Tract Infection Following Transrectal Ultrasound Guided Prostate Biopsy at a Tertiary-Care Medical Center in LebanonInfection Control, 2004
- Empirical Management of Urinary Tract Infections Complicating Transrectal Ultrasound Guided Prostate BiopsyJournal of Urology, 2003
- Single Dose Levofloxacin Prophylaxis for Prostate Biopsy in Patients at Low RiskJournal of Urology, 2002
- Extended-Spectrum -Lactamase-Producing Escherichia coli and Klebsiella pneumoniae: Risk Factors for Infection and Impact of Resistance on OutcomesClinical Infectious Diseases, 2001